Oncotelic CEO buys 240,000 shares in open market

Oncotelic Therapeutics, Inc. Chairman and CEO Dr. Vuong Trieu reported an open-market purchase of company stock.

Rhea-AI Filing Summary

Oncotelic Therapeutics, Inc. Chairman and CEO Dr. Vuong Trieu reported an open-market purchase of company stock. On July 1, 2026, he bought 240,000 shares of Common Stock at a price of $0.0431 per share in his individual capacity.

Following this transaction, Dr. Trieu directly owned 94,124,319 shares of Common Stock. The filing also lists indirect holdings of 6,872,529 shares held by his spouse and 16,780,384 shares held by Autotelic Inc., providing a view of both his direct and indirect ownership stakes.

Insider Trade Summary

Net Buyer: 240,000 shares

Net Buy 3 txns

Insider Trieu Vuong

Role CHAIRMAN AND CEO

Bought 240,000 shs ($10K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	240,000	$0.0431	$10K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 94,124,319 shares (Direct); Common Stock — 16,780,384 shares (Indirect, By Autotelic Inc.); Common Stock — 6,872,529 shares (Indirect, By spouse)

Footnotes (1)

1. F1. On July 1, 2026, Dr. Vuong Trieu purchased 240,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.0431.

Key Figures

Open-market purchase size: 240,000 shares Purchase price: $0.0431 per share Direct holdings after transaction: 94,124,319 shares +2 more

5 metrics

Open-market purchase size 240,000 shares Common Stock bought on July 1, 2026

Purchase price $0.0431 per share Price paid for 240,000 shares in open market

Direct holdings after transaction 94,124,319 shares Common Stock directly owned by Dr. Trieu after purchase

Indirect holdings by spouse 6,872,529 shares Common Stock held indirectly, by spouse

Indirect holdings by Autotelic Inc. 16,780,384 shares Common Stock held indirectly, by Autotelic Inc.

Key Terms

open market, Common Stock, indirect, individual capacity

4 terms

open market financial

"purchased 240,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.0431"

An open market is a system where buying and selling of goods, services, or financial assets happen freely without restrictions or special controls. For investors, it means they can trade assets easily and quickly, which helps determine fair prices based on supply and demand. This environment encourages transparency and competition, making it easier to buy or sell with confidence.

Common Stock financial

"Dr. Vuong Trieu purchased 240,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

indirect financial

"direct_or_indirect": "I","nature_of_ownership": "By spouse""

individual capacity financial

"Dr. Vuong Trieu purchased 240,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Oncotelic Therapeutics (OTLC) report for Dr. Vuong Trieu?

Oncotelic Therapeutics reported that Chairman and CEO Dr. Vuong Trieu purchased 240,000 shares of Common Stock. The shares were acquired on July 1, 2026 in an open-market transaction at $0.0431 per share, according to the Form 4 footnote.

At what price did the Oncotelic (OTLC) CEO buy additional shares?

Dr. Vuong Trieu bought 240,000 Oncotelic Therapeutics shares at $0.0431 per share. The purchase was made in the open market on July 1, 2026 and reflects an individual-capacity acquisition reported as a direct holding.

How many Oncotelic (OTLC) shares does Dr. Vuong Trieu own directly after the trade?

After the reported transaction, Dr. Vuong Trieu directly owns 94,124,319 shares of Oncotelic Therapeutics Common Stock. This figure comes from the Form 4 entry associated with the 240,000-share open-market purchase on July 1, 2026.

What indirect Oncotelic (OTLC) shareholdings are associated with Dr. Vuong Trieu?

The filing shows 6,872,529 shares held indirectly by Dr. Trieu’s spouse and 16,780,384 shares held indirectly by Autotelic Inc. These positions are reported as indirect ownership and are separate from his 94,124,319 directly held shares.

Is the Oncotelic (OTLC) insider transaction a purchase or sale?

The insider transaction is a purchase. The Form 4 identifies a code P transaction, described as an open-market purchase of 240,000 Oncotelic Therapeutics Common Stock shares by Dr. Vuong Trieu at $0.0431 per share on July 1, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/02/2026 - 03:00 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Trieu Vuong

(Last) (First) (Middle)

29397 AGOURA RD SUITE 107

(Street)

AGOURA HILLS CALIFORNIA 91301

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Oncotelic Therapeutics, Inc. [ OTLC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CHAIRMAN AND CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/01/2026(1)	07/01/2026(1)	P		240,000	A	$0.0431	94,124,319	D
Common Stock								16,780,384	I	By Autotelic Inc.
Common Stock								6,872,529	I	By spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On July 1, 2026, Dr. Vuong Trieu purchased 240,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.0431.

	/s/ Vuong Trieu	07/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)